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Cold extremities, peripheral numbness and frequent
muscle cramps are very commonly reported by pa-
tients with chronic kidney disease (CKD), and these
symptoms can be caused by peripheral ischemia re-
lated to peripheral artery occlusive disease (PAOD).
This problem is becoming more severe because of the
increasing number of diabetic and elderly patients
within the CKD and the dialysis populations. Previous
studies have reported the high prevalence of PAOD
and increased arterial stiffness in patients with renal
insufficiency [1–6]. Therefore, appropriate evaluation
of PAOD is important in the management of those
ischemic symptoms. The definition of PAOD included
the presence of obstructive lesions in the lower ex-
tremities. The ankle-brachial index (ABI) was reported
to be a good marker for atherosclerosis and useful 
in the diagnosis of PAOD, and an ABI < 0.9 has been
used to identify this condition in clinical practice and
in epidemiologic studies [7–9]. Brachial-ankle pulse
wave velocity (baPWV) has also been reported to be
a good marker for atherosclerosis or arterial stiffness
[10,11]. Careful evaluation using both techniques may
rationally provide more accurate and better evaluation
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High prevalences of peripheral artery occlusive disease (PAOD) and increased arterial stiffness
have been reported in patients with chronic kidney disease (CKD). However, these have not been
assessed in Taiwan where the prevalence of CKD is high. The aim of this study was to investigate
the determinants of PAOD and arterial stiffness in patients with CKD in southern Taiwan. We
enrolled 169 patients with stage 3–5 CKD in one regional hospital. Ankle-brachial index (ABI) and
brachial-ankle pulse wave velocity were measured using an ABI-form device (Colin VP1000). 
In multivariate analysis, ABI < 0.9 was positively correlated with the presence of diabetes melli-
tus (p = 0.014) and negatively correlated with the estimated glomerular filtration rate (eGFR)
(p = 0.049), and increased brachial-ankle pulse wave velocity was correlated with increased age,
diabetes mellitus, increased systolic blood pressure, decreased pulse pressure and decreased
eGFR. This study identified determinants of PAOD and arterial stiffness in patients with CKD in
one hospital in southern Taiwan. In addition to the traditional atherosclerotic risk factors,
decreased eGFR was also correlated with PAOD and increased arterial stiffness in these patients.
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of peripheral vascular damage. We have recently re-
ported the associated risk factors for abnormal ABI in
hemodialysis patients [12], but a similar study in CKD
patients has not been done in Taiwan. The aim of this
study was to evaluate the determinants of arterial
stiffness using ABI and baPWV in CKD patients in
southern Taiwan. Our results show that the presence
of decreased glomerular filtration rate (GFR), besides
old age and diabetes, is strongly correlated with both
ABI and baPWV and is an important determinant of
arterial stiffness in our CKD patients.
METHODS
Study patients and design
The study was conducted in a regional hospital in
southern Taiwan. We enrolled 169 (114 males and 
55 females) outpatients with stage 3–5 CKD accord-
ing to the National Kidney Foundation-Kidney Dis-
ease Outcomes Quality Initiative guidelines [13]. The
protocol was approved by our Institutional Review
Board and all enrolled patients gave written, informed
consent.
ABI and baPWV measurement
ABI and baPWV values were measured using an ABI-
form device (VP1000; Colin Co. Ltd., Komaki, Japan),
which automatically and simultaneously measures
the blood pressure (BP) in both arms and ankles using
an oscillometric method [14–16]. An ABI <0.9 is 95%
sensitive and 100% specific for angiographically doc-
umented PAOD in identifying healthy individuals
[17]. Meanwhile, baPWV is a known marker for ar-
terial stiffness, and was developed to screen large
populations [10,11]. ABI was calculated as the ratio 
of the ankle systolic BP divided by the arm systolic
BP, and the lowest ankle systolic BP value was used
in the calculation. To measure baPWV, pulse waves
obtained from the brachial and tibial arteries were
recorded simultaneously, and the transmission time
was determined as the time interval between the ini-
tial increase in brachial and tibial waveforms. The
transmission distance from the arm to each ankle was
calculated according to body height. The baPWV
value was automatically calculated as the transmis-
sion distance divided by the transmission time. After
obtaining bilateral baPWV values, the highest value
was considered representative for each subject. The
ABI and baPWV measurements were done once in
each patient.
Collection of demographic, medical and
laboratory data
Demographic and medical data including age, sex,
smoking history (ever vs. never) and comorbid con-
ditions were obtained from medical records and inter-
views with patients. The study subjects were defined
as having diabetes mellitus (DM) if the subject’s
medical data included an International Classification
of Diseases (9th edition) code of 250.00 to 250.90, or 
if the fasting blood glucose level was > 126 mg/dL, 
or if hypoglycemic agents were used to control blood
glucose levels. Hypertension was defined as an Inter-
national Classification of Diseases code of 401.9, di-
agnosis by a physician, systolic BP ≥ 140 mmHg or
diastolic BP ≥ 90 mmHg, or the subject was using
antihypertensive medications irrespective of BP. Cere-
brovascular disease was defined as a history of cere-
brovascular accident including cerebral bleeding and
infarction. Coronary artery disease was defined as a
history of angina, ischemic electrocardiogram change,
history of myocardial infarction, or having undergone
coronary bypass surgery or angioplasty. Body mass
index (BMI) was calculated as the ratio of weight in
kilograms divided by the square of height in meters.
Obesity was defined as BMI > 27 kg/m2 according to
criteria modified for Taiwanese subjects [18]. Labora-
tory data were measured from fasting blood samples
using an autoanalyzer (COBAS Integra 400; Roche
Diagnostics GmbH, Mannheim, Germany). The esti-
mated GFR (eGFR) was calculated using the simpli-
fied formula developed in the Modification of Diet in
Renal Disease study [19]. Serum intact parathyroid
hormone concentration was evaluated using a com-
mercially available two-site immunoradiometric assay
(CIS Bio International, Gif Sur Yvette, France). Blood
samples were obtained within 1 month of enrolment.
Urine albumin and creatinine were measured on a spot
urine sample by an autoanalyzer (COBAS Integra 400
Plus; Roche Diagnostics, North America) and albu-
minuria was defined as the ratio of urine albumin to
creatinine of ≥ 30 mg/g.
Statistical analysis
Statistical analysis was performed using SPSS ver-
sion 12.0 (SPSS Inc., Chicago, IL, USA) for Windows.
Data are expressed as percentages or mean ± standard
deviation. Logistic regression analysis and linear
regression analysis were used to identify the major
determinants of ABI < 0.9 and baPWV, respectively.
Age, sex and independent variables with a p value
< 0.2 in the univariate analysis were selected for mul-
tivariate analysis. A significant difference was con-
sidered when the p value was < 0.05.
RESULTS
The clinical characteristics of the patients in this study
are shown in Table 1. A total of 169 non-dialyzed CKD
patients were included. The mean age was 67.6 ±
12.4 years and there were 114 males and 55 females.
More than half of our patients (51.5%) were diabetic
and 84.6% received medications for high blood pres-
sure. Pre-existing and documented coronary arterial
and cerebrovascular diseases were noted in 20.7%
and 20.1% of patients, respectively. Overall, 47.3% of
patients had mildly impaired renal function (CKD
stage 3) and the other patients had more severe dis-
ease (29.6% in stage 4, 23.1% in stage 5). Obesity
(BMI > 27 kg/m2) was noted in 33.1% of patients. The
biochemical data are presented in Table 1. All of the
patients underwent ABI and baPWV measurement
and the prevalence of ABI < 0.9 was 8.3%. The aver-
age baPWV value was 2,040.3 ± 507.2 cm/s.
Table 2 shows the logistic regression analysis for
clinical determinants of ABI < 0.9 in our patients. In
univariate analyses, ABI < 0.9 was significantly asso-
ciated with decreased eGFR, older age, a history of
coronary artery disease or cerebrovascular disease,
decreased serum albumin, decreased cholesterol and
decreased hematocrit level. However, multiple logis-
tic regression analysis showed that ABI < 0.9 was only
positively correlated with the presence of DM and
negatively correlated with eGFR.
The analysis of determinants of baPWV in our
patients is presented in Table 3. In the univariate ana-
lyses, baPWV was positively correlated with age, DM,
history of cerebrovascular disease, systolic and dias-
tolic BP, pulse pressure and albuminuria, and nega-
tively correlated with eGFR, hematocrit and obesity.
Stepwise multivariate analysis showed that baPWV
was correlated with older age, DM, increased systolic
BP, decreased pulse pressure and decreased eGFR.
DISCUSSION
PAOD is prevalent in CKD patients and contributes to
multiple clinical ischemic symptoms and may affect
the rate of mortality of these patients [1,5,20]. Besides
clinical evaluation, ABI and baPWV are the two most
commonly used surrogate markers for peripheral
arterial stiffness—an advocate of PAOD in this study.
ABI < 0.9 has been shown to indicate PAOD, as docu-
mented by angiography, with high sensitivity and
specificity [17]. On the other hand, the measurement
of baPWV was found to be a simple and reliable
marker for arterial stiffness and was used as a screen-
ing tool in population studies [10,11]. In the present
study, we measured ABI and baPWV in CKD patients
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Table 1. Characteristics of all 169 study patients
Age (yr) 67.6 ± 12.4
Male sex (%) 67.5
Smoking history (%) 56.0
Diabetes mellitus (%) 51.5
Hypertension (%) 84.6
Coronary artery disease (%) 20.7
Cerebrovascular disease (%) 20.1
CKD stage
Stage 3 (%) 47.3
Stage 4 (%) 29.6
Stage 5 (%) 23.1
Systolic BP (mmHg) 142.7 ± 21.8
Diastolic BP (mmHg) 79.2 ± 12.3
Pulse pressure (mmHg) 62.8 ± 18.3
Body mass index > 27 (kg/m2) (%) 33.1
Laboratory parameters
Albumin (g/dL) 3.9 ± 0.4
Fasting glucose (mg/dL) 122.7 ± 47.5
Triglyceride (mg/dL) 167.9 ± 100.1
Cholesterol (mg/dL) 197.1 ± 47.4
eGFR (mL/min/1.73 m2) 28.2 ± 14.8
Hematocrit (%) 35.9 ± 6.9
Calcium (mg/dL) 9.5 ± 0.8
Phosphate (mg/dL) 4.0 ± 1.0
Ca × P (mg2/dL2) 36.7 ± 10.5
Uric acid (mg/dL) 8.3 ± 2.2
PTH (pg/mL) 75.6 ± 117.3
ABI < 0.9 (%) 8.3
baPWV (cm/s) 2,040.3 ± 507.2
CKD = chronic kidney disease; BP = blood pressure; eGFR =
estimated glomerular filtration rate; PTH = parathyroid hor-
mone; ABI = ankle-brachial index; baPWV = brachial-ankle
pulse wave velocity.
and found that DM and low eGFR were closely corre-
lated with these two parameters, as markers for arte-
rial stiffness. It has been stated that decreased eGFR
may predispose to atherosclerosis and arteriosclerosis,
and multiple pathogenic mechanisms are involved in
this process, including an imbalance between calcium
and phosphate, secondary hyperparathyroidism, ele-
vated homocysteine levels, lipoprotein(a) metabolism
and alterations in inflammatory and coagulation path-
ways [21]. Other factors such as fluid overload, alter-
ations in the angiotensin and endothelin systems,
malnutrition, elevated uremic toxins, oxidative stress
and insulin resistance have also been proposed [22].
A decrease in eGFR may, by itself, be considered 
as a marker for atherosclerosis and arteriosclerosis
contributing to arterial stiffness.
In our multivariate analysis of baPWV and arte-
rial stiffness (Table 2), increased age, DM, increased
systolic BP, decreased pulse pressure and eGFR were
found to be closely correlated. Most of our findings
were consistent with previous reports, except for
pulse pressure, which is reported differently in vari-
ous papers [2,4,5,20,23–26]. Stancanelli et al evalu-
ated the associated risk factors for aortic stiffness in
31 patients with CKD and found that increased pulse
pressure was an independent risk factor for aortic
stiffness [27]. Kawamoto et al also used aortic PWV
to evaluate arterial stiffness, and found that systolic
and diastolic BP, but not pulse pressure, were corre-
lated with increased aortic PWV [2]. In Nakagawa 
et al’s study, the results also showed no significant
correlation between baPWV and aortic stiffness [4].
Based on our own results, the increased pulse pres-
sure might negatively influence arterial stiffness. The
discrepancy between our own and other studies can-
not be explained in detail at the present time, but
ABI and baPWV in CKD patients
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Table 2. Determinants of ankle-brachial index < 0.9 in study patients
Univariate Multivariate
Parameter
Odds ratio (95% CI) p Odds ratio (95% CI) p
Age (per 1 yr) 1.060 (1.003–1.122) 0.040 1.020 (0.923–1.126) 0.701
Male vs. female 1.851 (0.495–6.926) 0.360 2.993 (0.290–30.880) 0.357
Smoking (ever vs. never) 0.406 (0.130–1.026) 0.121 0.206 (0.023–1.863) 0.160
Diabetes mellitus 2.532 (0.762–8.421) 0.130 12.088 (1.653–88.397) 0.014
Hypertension 1.099 (0.231–5.225) 0.905 – –
Coronary artery disease 3.259 (1.050–10.116) 0.041 2.163 (0.435–10.743) 0.346
Cerebrovascular disease 3.402 (1.094–10.582) 0.034 1.501 (0.287–7.858) 0.631
Systolic BP (per 1 mmHg) 1.002 (0.976–1.028) 0.878 – –
Diastolic BP (per 1 mmHg) 0.955 (0.910–1.002) 0.059 0.939 (0.879–1.004) 0.064
Pulse pressure (per 1 mmHg) 1.009 (0.979–1.040) 0.565 – –
Body mass index > 27 (kg/m2) 0.312 (0.067–1.444) 0.136 0.125 (0.014–1.116) 0.063
Laboratory parameters
Albumin (per 1 g/dL) 0.205 (0.075–0.559) 0.002 0.174 (0.028–1.060) 0.058
Fasting glucose (mg/dL) 1.003 (0.993–1.014) 0.509 – –
Triglyceride (per 1 mg/dL) 1.001 (0.996–1.006) 0.734 – –
Cholesterol (per 1 mg/dL) 0.983 (0.968–0.998) 0.028 0.989 (0.972–1.007) 0.220
eGFR (per 1 mL/min/1.73 m2) 0.952 (0.911–0.995) 0.028 0.922 (0.850–1.000) 0.049
Hematocrit (per 1%) 0.918 (0.845–0.998) 0.045 1.109 (0.917–1.342) 0.285
Calcium (per 1 mg/dL) 1.026 (0.506–2.080) 0.944 – –
Phosphate (per 1 mg/dL) 0.869 (0.476–1.587) 0.648 – –
Ca × P (per 1 mg2/dL2) 1.006 (0.955–1.061) 0.811 – –
Uric acid (per 1 mg/dL) 1.108 (0.876–1.401) 0.392 – –
PTH (per 1 pg/mL) 1.001 (0.996–1.005) 0.799 – –
Albuminuria 2.071 (0.444–9.665) 0.354 – –
CI = confidence interval; BP = blood pressure; eGFR = estimated glomerular filtration rate; PTH = parathyroid hormone.
may be related to the different study designs, different
patients recruited and the diverse associated diseases
in these patients.
Albuminuria is a known risk factor for atheroscle-
rosis and the subsequent development of cardiovascu-
lar diseases [28,29]. Some studies had noted increased
baPWV in subjects with hypertension or DM along
with proteinuria or albuminuria [30,31]. Ohya et al [6]
examined the relationship between proteinuria and
arterial stiffness in 3,387 people attending a health
program in Japan, and found that proteinuria and low
creatinine clearance were independently associated
with increased baPWV. Smith et al [32] found that
albuminuria and decreased renal function in patients
with type 2 diabetes were significantly associated with
baPWV. In our study, albuminuria was not correlated
with baPWV; thus, albuminuria was not a critical
determinant of increased baPWV in our patients.
The prevalence rate of peripheral arterial stiffness
was 8.3% in our study, which is lower than the 19.2–
38% in other reports [1,3,5,20]. ABI <0.9 was reported
to be a good surrogate marker for angiographically
confirmed PAOD [33]. However, falsely high values
were common. Another source of uncertainty is the
presence of incompressible “stiff” arteries (detected by
the measuring cuff) at the ankle level, which are com-
mon in patients with extensive vascular calcification,
such as patients with diabetes or being treated with
hemodialysis [26,34]. In the study by Fishbane et al,
the prevalence of ABI < 0.9 was 38% in 144 hemodi-
alysis patients and, of these, 25.4% were diabetic [7].
The marked difference between our and their data
(8.3% vs. 38%) may be explained by the different pa-
tient populations (undialyzed patients in our study vs.
patients undergoing hemodialysis in their study), and
the different prevalence of DM (51.5% vs. 25.4%,
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Table 3. Determinants of brachial-ankle pulse wave velocity in the study patients
Univariate Multivariate (stepwise)
Parameter
Standardized coefficient β p Standardized coefficient β p
Age (per 1 yr) 0.433 < 0.001 0.566 < 0.001
Male vs. female −0.085 0.275 – –
Smoking (ever vs. never) −0.018 0.813 – –
Diabetes mellitus 0.271 < 0.001 0.223 0.001
Hypertension 0.144 0.062 – –
Coronary artery disease 0.087 0.261 – –
Cerebrovascular disease 0.155 0.045 – –
Systolic BP (per 1 mmHg) 0.466 < 0.001 0.826 < 0.001
Diastolic BP (per 1 mmHg) 0.299 < 0.001 – –
Pulse pressure (per 1 mmHg) 0.357 < 0.001 −0.606 < 0.001
Body mass index > 27 (kg/m2) −0.222 0.004 – –
Laboratory parameters
Albumin (per 1 g/dL) −0.083 0.292 – –
Fasting glucose (mg/dL) 0.035 0.659 – –
Triglyceride (per 1 mg/dL) 0.077 0.322 – –
Cholesterol (per 1 mg/dL) −0.126 0.105 – –
eGFR (per 1 mL/min/1.73 m2) −0.184 0.017 −0.136 0.030
Hematocrit (per 1%) −0.229 0.003 – –
Calcium (per 1 mg/dL) 0.030 0.707 – –
Phosphate (per 1 mg/dL) −0.025 0.755 – –
Ca × P (per 1 mg2/dL2) 0.022 0.766 – –
Uric acid (per 1 mg/dL) 0.100 0.204 – –
PTH (per 1 pg/mL) 0.058 0.471 – –
Albuminuria 0.156 0.046 – –
BP = blood pressure; eGFR = estimated glomerular filtration rate; PTH = parathyroid hormone.
respectively), which predispose to stiff lower limb
vessels. Our own previous report revealed a higher
prevalence rate of low ABI in dialysis patients com-
pared with CKD patients [35]. In a study by de
Vinuesa et al, 32% of 102 CKD patients had ABI < 0.9,
but only 26% of them were diabetic [20]. Therefore,
the ABI values in CKD patients with diabetes may, 
in fact, be different from other patient populations,
but this assumption needs further observation and
consideration.
There are several limitations in our study. Our
study included patients at only one hospital and the
selection of patients might be biased; thus, our con-
clusion should not be extrapolated. In addition, this
was a cross-sectional study and we were unable to
predict the likelihood of PAOD or arterial stiffness.
Further studies are needed to measure the association
between baseline renal insufficiency with the progres-
sion of peripheral artery disease and future periph-
eral artery disease events. Finally, we did not measure
parameters associated with atherosclerosis, such as
C-reactive protein levels.
In conclusion, our study revealed the determinants
of peripheral arterial stiffness in patients with CKD
in Taiwan. Besides the well-known traditional ather-
osclerotic risk factors, a decreased eGFR was strongly
correlated with increased arterial stiffness in such
patients.
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在慢性腎臟病病人報告指出有高盛行率的周邊動脈阻塞疾病及動脈硬化增加的情形。
但在高慢性腎臟病盛行率的台灣卻很少探討。此篇文章即探討南台灣慢性腎臟病病人
周邊動脈疾病及動脈硬化的相關危險因子。我們收集了一間區域醫院 169 位慢性腎臟
病第 3 期到第 5 期病患。我們以 ABI-form (Colin VP 1000) 的儀器來為病人測量踝
臂血壓比及臂踝脈搏傳遞速度。經過多變量分析，踝臂血壓比 < 0.9 與糖尿病 (p = 
0.014) 呈有意義正相關，而與腎絲球過濾率 (p = 0.049) 呈有意義負相關。另外，臂
踝脈搏傳遞速度的增加則與年紀較大 (p < 0.001)，糖尿病 (p = 0.001)，較高的收縮
壓 (p < 0.001)，脈壓降低 (p < 0.001) 及低的腎絲球過濾率 (p = 0.030) 呈有意義相
關。本篇文章提供在南台灣慢性腎臟病病人周邊動脈阻塞疾病及動脈硬化的相關危險
因子。在這群病人，除傳統的動脈粥狀硬化的危險因子以外，腎絲球過濾率的下降亦
與周邊動脈阻塞疾病及動脈硬化有相關性。
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